Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial

Margatho Deborah; Carvalho Nelsilene Mota; Eloy Larissa; Bahamondes Luis

首页> 外文期刊>The European journal of contraception & reproductive health care: the official journal of the European Society of Contraception >Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial

【24h】

Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial

机译：使用ENG避孕植入物或52mg LNG-IUS评估子宫内膜异位症相关疼痛的妇女的生物标志物：非较低的随机临床试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective: The aim of the study was to assess the serum levels of the following biomarkers in women with endometriosis-associated pelvic pain before and after six months of using the etonogestrel (ENG) contraceptive implant or the 52 mg levonorgestrel-releasing intrauterine system (LNG-IUS): cancer antigen (CA)-125, cluster of differentiation (CD) 23 and endometrial nerve fibre density.

机译：目的：该研究的目的是评估在使用Etonegestrel（ENG）避孕植入物或52mg左炔诺孕烯肠内系统（LNG -ius）：癌症抗原（CA）-125，分化簇（CD）23和子宫内膜神经纤维密度。

著录项

来源
《The European journal of contraception & reproductive health care: the official journal of the European Society of Contraception》 |2018年第5期|共7页
作者
Margatho Deborah; Carvalho Nelsilene Mota; Eloy Larissa; Bahamondes Luis;
展开▼
作者单位

Univ Estadual Campinas Dept Obstet &

Gynaecol Med Sch Caixa Postal 6181 BR-13084971 Campinas;

Univ Estadual Campinas Dept Obstet &

Gynaecol Med Sch Caixa Postal 6181 BR-13084971 Campinas;

Univ Estadual Campinas Dept Pathol Med Sch Campinas SP Brazil;

Univ Estadual Campinas Dept Obstet &

Gynaecol Med Sch Caixa Postal 6181 BR-13084971 Campinas;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类妇科学;
关键词
Biomarkers; CA-125; CD23; endometrial nerve fibres; endometriosis; etonogestrel implant; levonorgestrel-releasing intrauterine system;

机译：生物标志物;CA-125;CD23;子宫内膜神经纤维;子宫内膜异位症;Etonogestrel植入物;Levonorgestrel-释放宫内系统;

相似文献

外文文献
中文文献

1. Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial [J] . Margatho Deborah, Carvalho Nelsilene Mota, Eloy Larissa, The European journal of contraception & reproductive health care: the official journal of the European Society of Contraception . 2018,第5期

机译：使用ENG避孕植入物或52mg LNG-IUS评估子宫内膜异位症相关疼痛的妇女的生物标志物：非较低的随机临床试验
2. Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months [J] . The European journal of contraception & reproductive health care: the official journal of the European Society of Contraception . 2020,第2期

机译：子宫内膜异位症相关的疼痛分数和生物标志物在Etonogestrel-释放的底切割植入物或52mg左旋血糖释放的宫内系统长达24个月
3. A two-arm parallel double-blind randomised controlled pilot trial of the efficacy of Omega-3 polyunsaturated fatty acids for the treatment of women with endometriosis-associated pain (PurFECT1) [J] . Ibtisam M. Abokhrais, Fiona C. Denison, Lucy H. R. Whitaker, PLoS One . 2020,第1期

机译：双臂平行双盲随机控制试验试验试验试验试验试验ω-3多不饱和脂肪酸治疗患有子宫内膜异位症相关的疼痛的疗效（purfect1）
4. Alginate Selection for Clinical Trial Evaluation of a Tissue Engineered Bulking Agent:Composition, Gel Properties, and In Vivo Performance Assessment [C] . Kermit Borland, Jim Birkhead, Tao Zhou, Annual meeting of the Society For Biomaterials . 2002

机译：用于组织工程膨胀剂临床试验评估的藻酸盐选择：组成，凝胶性质和体内性能评估
5. Clinical and cost-effectiveness of an online-delivered group-based pain management programme in improving pain-related disability for people with persistent pain—protocol for a non-inferiority randomised controlled trial (iSelf-help trial) [O] . Leigh Hale, Hemakumar Devan, Cheryl Davies, 2021

机译：在线提供的基于团体的基于团体的痛苦管理计划的临床和成本效益从而改善了对持续止痛协议的痛苦相关的残疾以获得非劣级的随机对照试验（ISELF-HELM帮助审判）
6. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY):A multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial [O] . Sivaprasad Sobha, Prevost A. Toby, Vasconcelos Joana C., 2017

机译：玻璃体腔注射阿柏西普与全视网膜光凝治疗52周增生性糖尿病视网膜病变患者的最佳矫正视力的临床疗效（CLARITY）：一项多中心，单盲，随机，对照，2b期非劣效性试验

Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial

摘要

著录项

相似文献

相关主题

期刊订阅